Shanghai Haoyuan Chemexpress and AbTis have reached a strategic cooperation to accelerate the development of the new generation of ADC drugs
On May 12, 2025, Shanghai Haoyuan Chemexpress Co., Ltd. (stock code: 688131, hereinafter referred to as "ChemExpress") officially signed a strategic cooperation agreement (MOU) with AbTis Co., Ltd. (hereinafter referred to as "AbTis"), a South Korean ADC biotechnology company.
Dr. Zheng Baofu, Chairman of ChemExpress（left）
Dr. Tae Dong Han, CEO of AbTis（right）
AbTis aims to utilize AbClick®, which is AbTis' proprietary site-selective antibody conjugate technology platform, to improve the safety and effectiveness of existing ADCs to enhance the treatment outcomes for cancer patients. ChemExpress will fully leverage its professional advantages from early discovery stage to commercial scale in ADC CDMO in specialized fields, and after establishing the deep cooperation with AbTis, both parties will integrate cutting-edge site-selective antibody conjugate technology and comprehensive ADC research and development capabilities, providing clients with innovative and efficient solutions.
AbClick® created a simple, efficient, and low-cost coupling technology that can accurately control the key parameters such as half-life, DAR, the stability of linker-payload, which can provide a feasible solution for exploring the optimal ADC drug. And ChemExpress has a one-stop ADC R&D and GMP production platform. The deep cooperation between the two parties will empower ADC innovative drug companies to accelerate the development of innovative ADC pipelines with differentiated clinical advantages.
The strategic cooperation between ChemExpress and AbTis includes but is not limited to site-selective antibody conjugate technology platform AbClick®.This strategic cooperation will promote ChemExpress to further deepen its involvement in the ADC field. Both parties will fully leverage their core advantages in antibody conjugate technology and industrialization, and accelerate the development process of new generation ADC drugs through deep collaborative innovation. This cooperation will not only enhance the competitiveness of the global ADC industry chain, but also promote innovative therapies to benefit patients in urgent need of treatment as early as possible, creating lasting value for human health.
Dr. Tae Dong Han, CEO of AbTis
As one of the earliest companies in China began the research in ADC, ChemExpress owns profound technical accumulation and professional talent advantages. The collaborative integration of AbClick® technology platforms with ChemExpress will continue to deepen the application of proprietary site-selective antibody conjugate technology, effectively promote the innovation process of ADC therapy breakthrough, bring treatment plans of more clinically valuable, safer and more effective precision to patients worldwide, and jointly create a new era in the field of ADC therapy.
Dr. Zheng Baofu, Chairman of ChemExpress
We are very pleased to have reached a strategic cooperation with AbTis, which owns the third-generation antibody conjugation technology platform AbClick® with independent intellectual property rights. ChemExpress has the ability to serve the research and production of ADC drugs for clients home and abroad. This cooperation will further leverage the advantages of both parties in their respective fields, help accelerate the development process of new generation ADC drugs and bioconjugate drugs, promote communication and integration at home and abroad, and benefit global patients as early as possible.
About AbTis
AbTis is a biotechnology company with a proprietary 3rd generation linker platform, AbClick®, which enables the development of site-selective antibody conjugate therapies for the targeted delivery of diverse therapeutic payloads. Through AbClick®, AbTis has established a simple yet cost-efficient conjugation process that empowers the expansion of diverse forms of bioconjugate treatments, such as ADC, ARC, DAC, and others, all without modifying the antibody. AbClick® also allows for precise control over key parameters such as half-life, DAR, and linker-payload stability, which are all essential for designing optimal bioconjugate therapies. AbTis has forged growing number of collaborations to develop best-in-class therapeutic candidates while developing its own pipelines for clinical developments. Acquired by Dong-A ST in 2023, AbTis strives to develop innovative therapies with an unwavering drive to provide therapies to patients in need. For more information, please refer to www.abtis.co.kr
About ChemExpress
Founded in 2006, Shanghai Haoyuan Chemexpress Co., Ltd. ("ChemExpress") specializes in offering CRO&CDMO services for pharmaceutical and biotech companies, focusing on small molecules, antibodies and new modalities such as ADCs\XDCs, peptides and PROTACs. Our comprehensive platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. We support our clients' projects from early drug discovery, process development to commercialization.